Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.
about
Biosimilars in the management of neutropenia: focus on filgrastimOver- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.How we manage autologous stem cell transplantation for patients with multiple myelomaUpdate on the safety and bioequivalence of biosimilars - focus on enoxaparin.Biosimilars: Implications for health-system pharmacists.Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Regulatory and clinical considerations for biosimilar oncology drugsBiosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantationComparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).Biosimilars in 3D: definition, development and differentiationBiosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator ProductComparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
P2860
Q26764906-CCD8214A-0500-4986-8705-F5A57F9B2F01Q33599892-DC3840B1-FE1F-475E-AD36-34D807F09AEDQ34019581-D4564F86-1394-4570-A06F-0B6FE0A5BAD3Q34352446-921002A5-C80B-4AE6-B617-D076245471D1Q34372394-6C516F27-F765-4377-AE1D-2C8D96D335C1Q34486159-9CDBE0CB-1023-4B47-9B60-28FFF9C00753Q35505833-8084F157-4F80-4210-8DFB-A67173BA1AAFQ35835005-72CA37EE-A412-4D68-A3A0-D0EC5264FB84Q36000209-92D4D6A1-733C-4F8A-9E99-42077FDC5D70Q37373201-5619FF09-5766-49EB-BD39-EDBD184575DEQ38186025-FE8549C4-573D-4F66-A537-482147E0345EQ38726241-7413C6B9-C3F3-4E11-9B93-B36ABC993D62Q40094120-C5E32D90-645C-485C-A9DF-1F248BB12A54Q40141879-CC431BAC-0D42-4734-9C5F-65323399556FQ41961612-F121A731-0E1B-40A7-BCB9-E9BF3809D2F4Q46922809-9C8F3A0A-301C-4FAF-8DB2-F958697DA67CQ47908189-E798B782-A6DF-4121-BF51-6156E9A5CA32Q47965968-4DDB4814-5446-4AAF-8674-58476BB09E15Q50042993-00068F95-855A-440C-8C5D-97E4BCDB72D2Q57049370-34426D8F-2AC8-4533-A356-0F8C91EAE611Q58806308-0D179166-1C62-4814-8458-0C690FD8756C
P2860
Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.
@en
type
label
Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.
@en
prefLabel
Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.
@en
P2093
P2860
P1476
Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.
@en
P2093
Ivo Abraham
Karen MacDonald
Soba Tharmarajah
P2860
P304
P356
10.1517/14740338.2013.770472
P407
P577
2013-02-18T00:00:00Z